Medtech Matters

Medical Product Outsourcing

A podcast focused on the medical device technology industry, from design and development to outsourcing services and relationships to finished medtech products.

  1. Sep 11

    A Preview of MDUFA VI: Changes and Highlights, Part 1

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re taking an early look at the next version of the Medical Device User Fee Act, MDUFA VI, which would go into effect in September 2027. The conversation involves changes to the pre-sub (or Q-sub) meeting with the agency as well as the possible addition of a fee associated with it. There’s also talk around potential changes for the de novo pathway. During this conversation, the following questions are addressed: What is the Medical Device User Fee Act (a.k.a., MUDFA) and why do we have it?Is there a downside to MUDFA?Medical device user fees have been around since 2003. So, what is new or noteworthy in the 2027 version?One update to the program would be to create a “focused follow-up pre-submission process” by the end of 2027, allowing sponsors to receive responses faster than with a traditional pre-submission request. Any comments on that?We have previously discussed in depth the de novo pathway to market, how it compares to the 510k, and the reasons why the de novo’s popularity has increased significantly over the past decade. Does MDUFA VI include any changes to the de novo?Listen to this discussion and then check out part 2 to hear the rest of the discussion. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com, and we’ll see if your ideas/inquiries/suggestions align with a  Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com.

  2. May 14

    FDA's Third-Party Review Program

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re discussing the FDA’s third-party review program. This option is available for certain 510k reviews. It is performed through an independent organization that is not part of the agency. As such, there are additional costs involved but the time savings could potential make up for that added expense. Other factors and considerations are also reviewed. During this conversation, the following questions are addressed: If I need to get a 510k clearance on my new medical device, is going through the FDA my only option?Under what circumstances should a sponsor consider using the third-party review program?Under what circumstances should a sponsor not consider using the third-party review program?How popular is the third-party review program, i.e., why are many people not familiar with it?Can you provide some examples of devices that have gone through the third-party review program.What advice would you provide in choosing which third-party review organization to work with?What are the key steps when considering using the third-party review program?When evaluating potential third-party review organizations, do you have recommendations on what questions to ask?Is there anything like the third-party review program outside the US, i.e. is there any regulatory precedent?What else is important, and what are today’s takeaways?Listen to this discussion and see if you may have interest in the third-party review program. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com, and we’ll see if your ideas/inquiries/suggestions align with a future episode. Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com.

  3. Apr 17

    Triaging Your QMS: Considerations Based on the New QMSR

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re discussing the FDA’s recently implemented QMSR. It went into effect on February 2nd and replaced 21 CFR Part 820. The regulation incorporates ISO 13485:2016, which is expected to help align medical device regulations globally. In this podcast, we focus on what device manufacturers should be doing now and what can wait for a later time. During this conversation, the following questions are addressed: As most are already familiar with QMS and now QMSR, we’ll dive deeper. Can you tell me if all sections of the QMSR listed in the QSR are required for all medical devices?Is a full QMS required to be in place in order to secure FDA clearance or approval?What about the sections of the QMSR? Are all of them equal in terms of importance? Are some sections more important than others?When do I need to have a QMS in place?What if I never intend to market my device? First, maybe provide an example of when that would be the case, and then address the first part.Should all QMS systems look the same?Are there differences with the QMSR with premarket vs. postmarket?How do you know the QMS is working? How can you be sure?What are the important takeaways from today’s session?Listen to this discussion and see if you are compliant with the new QMSR. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com, and we’ll see if your ideas/inquiries/suggestions align with a future episode. Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com.

4.8
out of 5
5 Ratings

About

A podcast focused on the medical device technology industry, from design and development to outsourcing services and relationships to finished medtech products.

You Might Also Like